Our top pick for
Zynex, Inc is a medical devices business based in the US. Zynex shares (ZYXI) are listed on the NASDAQ and all prices are listed in US Dollars. Zynex employs 283 staff and has a trailing 12-month revenue of around USD$68.7 million.
|52-week range||USD$7.93 - USD$29.73|
|50-day moving average||USD$17.6821|
|200-day moving average||USD$15.6424|
|Wall St. target price||USD$25.7|
|Dividend yield||N/A (0.88%)|
|Earnings per share (TTM)||USD$0.3|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Zynex stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zynex's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Zynex's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 60x. In other words, Zynex shares trade at around 60x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Zynex's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$13 million.
The EBITDA is a measure of a Zynex's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$68.7 million|
|Operating margin TTM||17.01%|
|Gross profit TTM||USD$36.8 million|
|Return on assets TTM||16.28%|
|Return on equity TTM||28.99%|
|Market capitalisation||USD$628.6 million|
TTM: trailing 12 months
There are currently 6.1 million Zynex shares held short by investors – that's known as Zynex's "short interest". This figure is 2.5% down from 6.2 million last month.
There are a few different ways that this level of interest in shorting Zynex shares can be evaluated.
Zynex's "short interest ratio" (SIR) is the quantity of Zynex shares currently shorted divided by the average quantity of Zynex shares traded daily (recently around 777441.74135723). Zynex's SIR currently stands at 7.81. In other words for every 100,000 Zynex shares traded daily on the market, roughly 7810 shares are currently held short.
However Zynex's short interest can also be evaluated against the total number of Zynex shares, or, against the total number of tradable Zynex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zynex's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 Zynex shares in existence, roughly 170 shares are currently held short) or 0.3321% of the tradable shares (for every 100,000 tradable Zynex shares, roughly 332 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Zynex.
Find out more about how you can short Zynex stock.
We're not expecting Zynex to pay a dividend over the next 12 months.
Zynex's shares were split on a 1:40 basis on 16 December 2003. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Zynex shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Zynex shares which in turn could have impacted Zynex's share price.
Over the last 12 months, Zynex's shares have ranged in value from as little as $7.93 up to $29.73. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zynex's is 0.8549. This would suggest that Zynex's shares are less volatile than average (for this exchange).
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.